Prophylactic fluconazole and candida krusei infections

Janice Y. Tam, Karl G. Blume, Charles G. Prober, René Olivier Casasnovas, Denis Caillot, Eric Solary, Bernard Bonotte, Pascal Chavanet, Alain Bonin, Patrick Camerlynck, Henri Guy, U. Schuler, G. Ehninger, John R. Wingard, William G Merz, Michael G. Rinaldi, Judith E. Karp, Rein Saral, James W. Hathorn

Research output: Contribution to journalLetterpeer-review

Abstract

To the Editor: In the October 31 issue of the Journal, Wingard et al.* reported the results of their retrospective study of the incidence and types of fungal infections in patients who had leukemia or who had undergone bone marrow transplantation. Some of the patients received no antifungal prophylaxis, whereas others received oral fluconazole, intravenous miconazole, or low-dose intravenous amphotericin B. A twofold greater incidence of colonization and a sevenfold greater frequency of infection caused by Candida krusei were noted in the 84 patients who received prophylactic fluconazole as compared with the 335 patients who did not. Nine of.

Original languageEnglish (US)
Pages (from-to)891-893
Number of pages3
JournalNew England Journal of Medicine
Volume326
Issue number13
DOIs
StatePublished - Mar 26 1992
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Prophylactic fluconazole and candida krusei infections'. Together they form a unique fingerprint.

Cite this